Beyond OTOF: What's Next in the Gene Therapy Pipeline for Genetic Hearing Loss

Why Was OTOF the First Target for Hearing Gene Therapy?

Mutations in the OTOF gene cause auditory neuropathy by disabling otoferlin, a protein essential for transmitting sound signals from hair cells to the auditory nerve. Unlike many forms of genetic deafness, the cochlear hair cells themselves remain structurally normal, meaning that delivering a functional OTOF gene can restore signaling without needing to regenerate damaged cells. This made it an attractive early target for adeno-associated virus (AAV) delivery.

The recently approved therapy uses a single intracochlear injection of an AAV vector carrying a functional copy of OTOF. Early clinical data published in The Lancet and presented by several international research groups, including teams at Children's Hospital of Philadelphia and Fudan University, showed meaningful hearing recovery in treated children. However, OTOF mutations account for only a small fraction of all hereditary hearing loss cases — estimates range from roughly 1 to 8 percent of congenital sensorineural deafness, depending on the population studied.

Which Genetic Hearing Disorders Could Be Treated Next?

GJB2, which encodes the protein connexin 26, is the single most common cause of non-syndromic genetic hearing loss worldwide. Because GJB2 affects supporting cells in the cochlea rather than hair cells directly, developing gene therapy for this target has been more scientifically challenging, but several academic laboratories and biotechnology companies have active preclinical programs. TMC1, which affects mechanotransduction in hair cells, is another leading candidate, with work from the Boston Children's Hospital gene therapy group showing encouraging results in animal models.

Beyond simple gene replacement, researchers are also exploring base editing and other CRISPR-derived approaches for dominant-negative mutations, where adding a functional gene alone would not be sufficient. Usher syndrome, which combines deafness with progressive vision loss, is another area of intense research interest because it represents a combined sensory disorder that could benefit from dual-tissue gene therapy strategies.

How Does Gene Therapy Compare With Cochlear Implants?

Cochlear implants have transformed outcomes for children with profound hearing loss for decades and remain widely available, well-studied, and reimbursed by most insurance systems. They bypass damaged sensory cells entirely by electrically stimulating the auditory nerve. Gene therapy, by contrast, aims to restore natural biologic hearing at the molecular level, which may allow more natural sound perception and better performance in complex listening environments — though long-term durability data are still being collected.

For the foreseeable future, gene therapy is expected to complement rather than replace cochlear implants. It is currently appropriate only for specific genetic diagnoses confirmed through genetic testing, and only for patients whose cochlear anatomy is suitable for vector delivery. Cost, access, and the need for specialized surgical expertise remain significant barriers, and clinicians emphasize that early genetic testing in infants with hearing loss will become increasingly important as more targeted therapies reach clinical use.